Aclaris Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Clinical-stage specialty pharmaceutical company focused on dermatology. The report covers the quarter and nine months ended September 30, 2016, filed November 3, 2016. Lead candidate A-101 was in three Phase 3 trials for seborrheic keratosis; enrollment was completed in the third quarter. The company had no product revenue and had not achieved profitable operations.
Financial Highlights
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $7.2 million | $26.5 million |
| General and administrative expense | $3.7 million | $10.4 million |
| Operating loss | $10.8 million | $36.9 million |
| Net loss | $10.7 million | $36.6 million |
| Net loss per share | $0.50 | $1.76 |
| Operating cash flow | Not provided for the quarter | $(26.5) million |
Margins are not meaningful because the company generated no revenue. At September 30, 2016, cash and cash equivalents were $17.8 million, marketable securities were $66.2 million, and total liquidity was $84.0 million. Total assets were $86.1 million, total liabilities were $4.9 million, and stockholders’ equity was $81.1 million. The filing reports no ongoing material financing commitments such as lines of credit or guarantees; debt was not identified as a material balance-sheet item.
Material Changes Versus Prior Comparable Period
- Nine-month net loss increased to $36.6 million from $15.8 million, primarily reflecting expanded clinical and preclinical development.
- Nine-month R&D expense increased $13.6 million, driven by A-101 seborrheic keratosis development, JAK-inhibitor programs, increased headcount, and stock-based compensation. The prior-year period included an $8.0 million Rigel upfront payment that did not recur.
- Nine-month G&A expense increased $7.5 million, reflecting higher personnel and stock-based compensation, public-company costs, market research, Vixen-related legal and patent expenses, and a $0.3 million A-101 milestone payment.
- Operating cash usage increased from $16.2 million to $26.5 million.
- Investing activities provided $15.9 million in 2016, primarily from sales and maturities of marketable securities, compared with $7.5 million of cash used in the prior-year period.
- Financing activities provided $18.6 million, principally from the June 2016 private placement of 1,081,082 common shares for net proceeds of $18.5 million.
- The March 2016 Vixen acquisition added JAK-inhibitor assets and resulted in approximately $3.4 million of R&D expense, including cash, stock, and the present value of annual payments.
Guidance, Outlook, Risks, and Unusual Items
Management expected to report Phase 3 A-101 seborrheic keratosis results in the fourth quarter of 2016. Subject to favorable results, it planned to submit an FDA NDA in the first quarter of 2017 and a European Marketing Authorization Application in mid-2017. The company also planned development of A-101 for common warts, A-102, and ATI-50001 and ATI-50002 for alopecia areata and related dermatological conditions.
Management stated that existing cash, cash equivalents, and marketable securities were expected to fund operating and capital requirements for more than 12 months from September 30, 2016, based on current assumptions. Additional capital would likely be required for commercialization, further development, and potential acquisitions or licenses. The company expected continued operating losses and significant expenses for the foreseeable future.
- Clinical-trial results, enrollment, regulatory approval, manufacturing, commercialization, and market acceptance remain uncertain.
- Additional financing may be unavailable or dilutive and could be needed sooner than expected if development costs or timelines increase.
- Material contingent obligations include up to $80.0 million of pre-commercialization milestones and up to $10.0 million of additional development milestones under the Rigel license, plus royalties.
- Vixen-related obligations include up to $18.0 million of pre-commercialization milestones, $22.5 million of commercial milestones, annual payments, and royalties. Columbia University obligations include up to $11.6 million of commercial milestones and royalties.
- The company had $847,000 of remaining sublease commitments as of September 30, 2016 and potential intellectual-property, supply, milestone, and royalty obligations.
- No material legal proceedings were reported. Management stated that disclosure controls were effective and that there were no material changes in internal control over financial reporting.
Key Facts for Investors to Verify
- Timing and results of the three Phase 3 A-101 seborrheic keratosis trials and the expected NDA submission.
- Cash burn relative to the stated liquidity runway and the timing and size of any future financing.
- Progress, costs, and regulatory status of the JAK-inhibitor programs acquired or licensed through Rigel, Vixen, and Columbia University.
- Potential milestone, royalty, licensing, supply-termination, and commercialization obligations.
- Patent scope and expiration dates, including A-101 patents scheduled to expire in 2022 and certain JAK-related patents scheduled to expire between 2023 and 2031.